Aurinia Pharmaceuticals Inc. Financing Cash Flow
Aurinia Pharmaceuticals Inc. (AUPH) reported Financing Cash Flow of -$48.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $4.81M.
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$53.69M.
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$1.89M.
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$10.49M.
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) financing activities for fiscal 2025 was -$106.11M.
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) financing activities for fiscal 2024 was -$49.09M.
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) financing activities for fiscal 2023 was -$5.13M, a 310.85% decline from fiscal 2022.
- Aurinia Pharmaceuticals Inc. net cash provided by (used in) financing activities for fiscal 2022 was $2.43M, a 98.90% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$48.88M 10-Q · filed 2026-08-06 | -$50.76M derived: sum of 3 quarters · filed 2026-08-06 | -$61.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$53.69M 10-Q · filed 2026-05-07 | -$55.57M derived: sum of 2 quarters · filed 2026-05-07 | -$66.06M derived: sum of 3 quarters · filed 2026-05-07 | -$110.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$12.38M derived: sum of 2 quarters · filed 2026-02-26 | -$56.77M derived: sum of 3 quarters · filed 2026-08-06 | -$106.11M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$10.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$54.88M derived: sum of 2 quarters · filed 2026-08-06 | -$104.22M 10-Q · filed 2025-11-04 | -$127.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$44.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$93.73M 10-Q · filed 2026-08-06 | -$116.78M derived: sum of 3 quarters · filed 2026-08-06 | -$119.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$49.34M 10-Q · filed 2026-05-07 | -$72.38M derived: sum of 2 quarters · filed 2026-05-07 | -$75.11M derived: sum of 3 quarters · filed 2026-05-07 | -$83.38M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$23.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$25.77M derived: sum of 2 quarters · filed 2026-02-26 | -$34.04M derived: sum of 3 quarters · filed 2026-02-26 | -$49.09M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$2.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$10.99M derived: sum of 2 quarters · filed 2025-11-04 | -$26.05M 10-Q · filed 2025-11-04 | -$31.62M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$8.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$23.32M 10-Q · filed 2025-07-31 | -$28.90M derived: sum of 3 quarters · filed 2026-02-26 | -$31.23M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$15.05M 10-Q · filed 2025-05-12 | -$20.63M derived: sum of 2 quarters · filed 2026-02-26 | -$22.96M derived: sum of 3 quarters · filed 2026-02-26 | -$21.82M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$7.91M derived: sum of 2 quarters · filed 2026-02-26 | -$6.77M derived: sum of 3 quarters · filed 2026-02-26 | -$5.13M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.19M derived: sum of 2 quarters · filed 2024-11-07 | $447.00K 10-Q · filed 2024-11-07 | $1.14M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $2.78M 10-Q · filed 2024-08-01 | $3.47M derived: sum of 3 quarters · filed 2025-02-27 | $3.47M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.64M 10-Q · filed 2024-05-02 | $2.33M derived: sum of 2 quarters · filed 2025-02-27 | $2.33M derived: sum of 3 quarters · filed 2025-02-27 | $3.67M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $688.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $688.00K derived: sum of 2 quarters · filed 2025-02-27 | $2.03M derived: sum of 3 quarters · filed 2025-02-27 | $2.43M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.34M derived: sum of 2 quarters · filed 2023-11-02 | $1.75M 10-Q · filed 2023-11-02 | $207.47M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.75M 10-Q · filed 2023-08-03 | $207.47M derived: sum of 3 quarters · filed 2024-02-15 | $216.55M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $405.00K 10-Q · filed 2023-05-04 | $206.13M derived: sum of 2 quarters · filed 2024-02-15 | $215.21M derived: sum of 3 quarters · filed 2024-02-15 | $216.49M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $205.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $214.80M derived: sum of 2 quarters · filed 2024-02-15 | $216.08M derived: sum of 3 quarters · filed 2024-02-15 | $221.11M 10-K · filed 2024-02-15 |
| 2021-09-30 | $9.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $10.36M derived: sum of 2 quarters · filed 2022-11-03 | $15.39M 10-Q · filed 2022-11-03 | $16.63M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $6.31M 10-Q · filed 2022-08-04 | $7.55M derived: sum of 3 quarters · filed 2023-02-28 | $196.81M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $5.03M 10-Q · filed 2022-05-10 | $6.27M derived: sum of 2 quarters · filed 2023-02-28 | $195.53M derived: sum of 3 quarters · filed 2023-02-28 | $196.48M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $190.50M derived: sum of 2 quarters · filed 2023-02-28 | $191.45M derived: sum of 3 quarters · filed 2023-02-28 | $194.38M 10-K · filed 2023-02-28 |
| 2020-09-30 | $189.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $190.21M derived: sum of 2 quarters · filed 2021-11-03 | $193.13M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $954.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $3.88M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $2.92M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $243.85M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $4.01M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |